Marjorie Roesser focuses her practice on the representation of both issuers and underwriters on a broad range of capital markets transactions, including initial public offerings and other public and private equity offerings, as well as high-yield, investment-grade and convertible debt issuances. Marjorie also regularly advises clients on general corporate matters, including SEC reporting and corporate governance.

Download full bio 


  • Pliant Therapeutics – $230.0 Million Follow-on Offering 

  • Sweetgreen – $418.6 Million IPO 

  • Lulu’s – $92 Million IPO 

  • PROCEPT BioRobotics – $188.5 Million IPO 

  • Doximity – $697 Million IPO 

  • View all


  • Harvard Law School
    JD, 2018

  • University of Southern California
    BS, Business Administration
    magna cum laude, 2012

Admissions & Credentials


Media & Insight